Patents by Inventor Anje Cauwels

Anje Cauwels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibroblast binding agents and use thereof
    Patent number: 11896643
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: February 13, 2024
    Assignee: Orionis Biosciences, Inc.
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels
  • THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
    Publication number: 20240025980
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Anje CAUWELS
  • Therapeutic targeting of non-cellular structures
    Patent number: 11753463
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Leander Huyghe, Anje Cauwels
  • CLEC9A BINDING AGENTS
    Publication number: 20220356253
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: April 5, 2021
    Publication date: November 10, 2022
    Inventors: Jan TAVERNIER, Nikolai KLEY, Anje CAUWELS, Sarah GERLO
  • CD20 BINDING SINGLE DOMAIN ANTIBODIES
    Publication number: 20220185904
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Jan TAVERNIER, Anje CAUWELS, José VAN DER HEYDEN
  • CD8 BINDING AGENTS
    Publication number: 20220177586
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 9, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Sarah GERLO
  • MODULATION OF DENDRITIC CELL LINEAGES
    Publication number: 20220119472
    Abstract: The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 21, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, Erik DEPLA
  • CD20 binding single domain antibodies
    Patent number: 11248057
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Anje Cauwels, José Van Der Heyden
  • CD8 binding agents
    Patent number: 11236166
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 1, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, UNIVERSITEIT GENT
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels, Sarah Gerlo
  • THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
    Publication number: 20210238264
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 5, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Anje CAUWELS
  • BISPECIFIC SIGNALING AGENTS AND USES THEREOF
    Publication number: 20210139586
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Application
    Filed: December 21, 2020
    Publication date: May 13, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Sandra VAN LINT, Anje CAUWELS
  • Clec9A binding agents
    Patent number: 11001631
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 11, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
  • Bispecific signaling agents and uses thereof
    Patent number: 10988538
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: April 27, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Sandra Van Lint, Anje Cauwels
  • FIBROBLAST BINDING AGENTS AND USE THEREOF
    Publication number: 20210023167
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: February 5, 2019
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS
  • BISPECIFIC SIGNALING AGENTS AND USES THEREOF
    Publication number: 20190367604
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 5, 2019
    Inventors: Nikolai KLEY, Jan TAVERNIER, Sandra VAN LINT, Anje CAUWELS
  • CLEC9A BINDING AGENTS
    Publication number: 20190352406
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: February 6, 2017
    Publication date: November 21, 2019
    Inventors: Jan TAVERNIER, Nikolai KLEY, Anje CAUWELS, Sarah GERLO
  • CD20 BINDING SINGLE DOMAIN ANTIBODIES
    Publication number: 20190092871
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 28, 2019
    Inventors: Jan TAVERNIER, Anje CAUWELS, José VAN DER HEYDEN
  • CD8 BINDING AGENTS
    Publication number: 20190071500
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: February 6, 2017
    Publication date: March 7, 2019
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Sarah GERLO
  • Targeting of interleukin-1 and -18 signaling in treatment of septic shock
    Patent number: 9919048
    Abstract: The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: March 20, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT
    Inventors: Peter Vandenabeele, Anje Cauwels, Tom Vandenberghe
  • TARGETING OF INTERLEUKIN-1 AND -18 SIGNALING IN TREATMENT OF SEPTIC SHOCK
    Publication number: 20160331837
    Abstract: The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Inventors: Peter Vandenabeele, Anje Cauwels, Tom Vandenberghe